With a consistent efficacy and safety profile through 56-weeks of follow-up, the Phase 3 SCOUT-HCM clinical trial further reinforces Camzyos as the first approved treatment for pediatric patients ≥30 kg with
Studies from Beth Israel Deaconess and the University of Colorado highlight how AI-ECG can help clinicians identify suspected cardiac disease from routine ECGs
Viz.ai, the leader in AI-powered disease detection and
DENVER, Oct. 29, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) As 2027 approaches, developments across the United States, Europe and Asia are giving patients, researchers and healthcare markets new reasons to pay
Bristol Myers Squibb (NYSE:BMY) today reported third quarter 2026 financial results.
Visit the company’s Investor Relations website at http://investor.bms.com to view the detailed third quarter 2026 earnings press
Late-breaking results to be presented in an oral presentation at ESMO 2026
PANKU-Lung01 is the first Phase 3 trial to evaluate a dual-targeting EGFRxHER3 bispecific antibody-drug conjugate in this patient
Pumitamig plus docetaxel demonstrated encouraging responses in squamous and non-squamous non-small cell lung cancer across PD-L1 expression levels with a confirmed objective response rate of 36.7% following progression
Data reinforce the potential for immune reset with zolacabtagene autoleucel to address an underlying cause of multiple sclerosis
Bristol Myers Squibb (NYSE:BMY) today announced disclosure of interim safety and
Tempus AI, Inc. (NASDAQ:TEM, "Tempus")) today announced a multi-year agreement with Bristol Myers Squibb (NYSE:BMY, "BMS")), under which BMS will license multimodal oncology data from Tempus through 2031
Funding follows rapid portfolio expansion and will power the initiation of a registrational study for AI-identified asset JSKN016
Pathos AI, Inc., a clinical-stage AI and technology company advancing its own
Tempus to build a de-identified dataset from hundreds of thousands of patients with neurological conditions; Pathos to license the dataset under a five-year, $55 million agreement
Pathos’s AI expertise and agentic
Late-breaking results to be presented in an oral presentation at ESMO 2026
With two positive Phase 3 trials in breast cancer, these data reinforce the potential of iza-bren to further redefine treatment across breast
Late-breaking Phase 3 disclosures for izalontamab brengitecan (iza-bren), a potential first-in-class EGFR × HER3 bispecific ADC, in EGFR-mutated non-small cell lung cancer (PANKU-Lung01) and HR+/HER2- breast cancer
The study met the primary endpoint with a statistically significant and clinically meaningful improvement in progression free survival (PFS)
Bristol Myers Squibb (NYSE:BMY) today announced positive topline results
In the trial, admilparant at the 60 mg dose demonstrated a statistically significant benefit in absolute change in forced vital capacity (FVC) from baseline to Week 52 compared with placebo
Admilparant demonstrated a
In the EXCALIBER study, results showed a progression-free survival hazard ratio of 0.49 compared with daratumumab, bortezomib and dexamethasone
Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in
